Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
11:46pm, Tuesday, 04'th Nov 2025
Veracyte, Inc. ( VCYT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executiv
Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates
07:26pm, Tuesday, 04'th Nov 2025
Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.19 per share a year ago.
Veracyte Announces Third Quarter 2025 Financial Results
04:05pm, Tuesday, 04'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “
Y Intercept Hong Kong Ltd Has $1.10 Million Stake in Veracyte, Inc. $VCYT
04:40am, Tuesday, 04'th Nov 2025
Y Intercept Hong Kong Ltd trimmed its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 11.5% during the second quarter, according to the company in its most recent disclosure with the Securities
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
04:15pm, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #AfirmaGRID--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating t
State of New Jersey Common Pension Fund D Buys 19,590 Shares of Veracyte, Inc. $VCYT
03:27am, Sunday, 02'nd Nov 2025
State of New Jersey Common Pension Fund D raised its stake in Veracyte, Inc. (NASDAQ: VCYT) by 39.9% during the undefined quarter, according to the company in its most recent 13F filing with the Secur
Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of “Moderate Buy” from Analysts
01:31am, Sunday, 26'th Oct 2025
Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Tw
Veracyte (VCYT) Crossed Above the 20-Day Moving Average: What That Means for Investors
10:36am, Thursday, 16'th Oct 2025
Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT crossed above the 20-day moving average, suggesting a sh
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
05:31pm, Wednesday, 15'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
10:02am, Tuesday, 07'th Oct 2025
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 29'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
04:00pm, Sunday, 28'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a
Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
10:31pm, Tuesday, 09'th Sep 2025
Veracyte, Inc. (NASDAQ:VCYT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP &
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 Americ
